GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hangzhou Jiuyuan Gene Engineering Co Ltd (HKSE:02566) » Definitions » Cash, Cash Equivalents, Marketable Securities

Hangzhou Jiuyuan Gene Engineering Co (HKSE:02566) Cash, Cash Equivalents, Marketable Securities : HK$127 Mil (As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Hangzhou Jiuyuan Gene Engineering Co Cash, Cash Equivalents, Marketable Securities?

Hangzhou Jiuyuan Gene Engineering Co's quarterly cash, cash equivalents, marketable securities increased from Jun. 2023 (HK$0.00 Mil) to Dec. 2023 (HK$137.97 Mil) but then stayed the same from Dec. 2023 (HK$137.97 Mil) to Jun. 2024 (HK$127.15 Mil).

Hangzhou Jiuyuan Gene Engineering Co's annual cash, cash equivalents, marketable securities declined from Dec. 2021 (HK$156.49 Mil) to Dec. 2022 (HK$129.52 Mil) but then increased from Dec. 2022 (HK$129.52 Mil) to Dec. 2023 (HK$137.97 Mil).


Hangzhou Jiuyuan Gene Engineering Co Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Hangzhou Jiuyuan Gene Engineering Co's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hangzhou Jiuyuan Gene Engineering Co Cash, Cash Equivalents, Marketable Securities Chart

Hangzhou Jiuyuan Gene Engineering Co Annual Data
Trend Dec21 Dec22 Dec23
Cash, Cash Equivalents, Marketable Securities
156.49 129.52 137.97

Hangzhou Jiuyuan Gene Engineering Co Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24
Cash, Cash Equivalents, Marketable Securities 156.49 129.52 - 137.97 127.15

Hangzhou Jiuyuan Gene Engineering Co Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Hangzhou Jiuyuan Gene Engineering Co  (HKSE:02566) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Hangzhou Jiuyuan Gene Engineering Co Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Hangzhou Jiuyuan Gene Engineering Co's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Hangzhou Jiuyuan Gene Engineering Co Business Description

Industry
Traded in Other Exchanges
N/A
Address
No. 23, Eighth Street Baiyang Street, Qiantang District, Zhejiang Province, Hangzhou, CHN
Hangzhou Jiuyuan Gene Engineering Co Ltd is a biopharmaceutical company in China. It is engaged in the research & development, manufacturing and commercialization of biopharmaceutical products and medical devices. The company focuses on four large and fast-growing therapeutic areas: orthopedics, metabolic diseases, oncology, and hematology. Centered around these therapeutic areas, It has built a diversified product portfolio comprising eight marketed products, including China's first recombinant human bone morphogenetic protein-2 (rhBMP-2) bone repair material, Guyoudao, and over ten product candidates, including the first semaglutide biosimilar in China to have obtained an IND approval and filed an NDA, JY29-2.
Executives
Zhong Guo Yuan Da Ji Tuan You Xian Ze Ren Gong Si
Bei Jing Yuan Da Hua Chuang Tou Zi You Xian Gong Si
Hua Dong Yi Yao Gu Fen You Xian Gong Si
Hang Zhou Zhong Mei Hua Dong Zhi Yao You Xian Gong Si
Zhe Jiang Wang Xin Ke Ji Chuang Tou You Xian Gong Si
Zhe Da Wang Xin Ke Ji Gu Fen You Xian Gong Si
Hu Kaijun
Hang Zhou He Da Tou Zi Guan Li You Xian Gong Si
Corporacion Quimico-farmaceutica Esteve, Sociedad Anónima 2101 Beneficial owner
Hang Zhou Hua Sheng Yi Yao Ji Tuan You Xian Gong Si
Hang Zhou Wan Yu He Yi Yao Ke Ji You Xian Gong Si
Li Bang Liang
Hang Zhou Qian Tang Xin Qu Guan Li Wei Yuan Hui
Hang Zhou Qian Tang Xin Qu Chan Ye Fa Zhan Ji Tuan You Xian Gong Si
Hang Zhou He Da Jin Rong Fu Wu Ji Tuan You Xian Gong Si

Hangzhou Jiuyuan Gene Engineering Co Headlines

No Headlines